ArticleHealth information science and systems2025
Identification and applications of disease-associated differential human and bacterial proteins with metaproteomic evidence.
Article in Health information science and systems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The gut microbiome plays a fundamental role in human health and disease. Individual variations in the microbiome and the corresponding functional implications are key considerations to enhance precision health and medicine. Metaproteomics has recently revealed protein expression that might be associated with human health and disease. Existing studies focused on either human proteins or bacterial proteins that can be identified from (meta)proteomics data sets, but not both. In this study, we examined the feasibility of identifying both human and bacterial proteins that are differentially expressed between healthy and diseased individuals from metaproteomics data sets. We further evaluated different strategies of using identified peptides and proteins for building predictive models. By leveraging existing metaproteomics data sets and a tool that we have developed for metaproteomics data analysis (MetaProD), we were able to derive both human and bacterial differentially expressed proteins that could serve as potential biomarkers for all diseases we studied. We also built predictive models using identified peptides and proteins as features for prediction of human diseases. Our results showed peptide-based identifications over protein-based ones often produce the most accurate models and that feature selection can offer improvements. Prediction accuracy could be further improved, in some cases, by including bacterial identifications, but missing data in bacterial identifications remains problematic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.